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ABSTRACT:
Tumor Necrosis Factor (TNF) interacts with two receptors known as TNFR1 and 
TNFR2. TNFR1 activation may result in either cell proliferation or cell death. TNFR2 
activates Nuclear Factor-kappaB (NF-kB) and c-Jun N-terminal kinase (JNK) which 
lead to transcriptional activation of genes related to cell proliferation and survival.  
This depends on the binding of TNF Receptor Associated Factor 2 (TRAF2) to the 
receptor. TNFR2 also induces TRAF2 degradation. In this work we have investigated 
the structural features of TNFR2 responsible for inducing TRAF2 degradation and have 
studied the biological consequences of this activity. We show that when TNFR1 and 
TNFR2 are co-expressed, TRAF2 depletion leads to an enhanced TNFR1 cytotoxicity 
which correlates with the inhibition of NF-kB. NF-kB activation and TRAF2 degradation 
depend of different regions of the receptor since TNFR2 mutants at amino acids 
343-349 fail to induce TRAF2 degradation and have lost their ability to enhance 
TNFR1-mediated cell death but are still able to activate NF-kB. Moreover, whereas 
NF-kB activation requires TRAF2 binding to the receptor, TRAF2 degradation appears 
independent of TRAF2 binding. Thus, TNFR2 mutants unable to bind TRAF2 are still 
able to induce its degradation and to enhance TNFR1-mediated cytotoxicity. To test 
further this receptor crosstalk we have developed a system stably expressing in cells 
carrying only endogenous TNFR1 the chimeric receptor RANK-TNFR2, formed by the 
extracellular region of RANK (Receptor activator of NF-kB) and the intracellular region 
of TNFR2.This has made possible to study independently the signals triggered by 
TNFR1 and TNFR2. In these cells TNFR1 is selectively activated by soluble TNF (sTNF) 
while RANK-TNFR2 is selectively activated by RANKL. Treatment of these cells with 
sTNF and RANKL leads to an enhanced cytotoxicity. 
INTRODUCTION.
TNF interacts with two receptors known as TNFR1 
and TNFR2. Soluble TNF (sTNF) only activates TNFR1, 
while membrane-bound TNF (mTNF) activates both 
receptors [1, 2]. Both TNFRs are highly similar in their 
extracellular regions which contain four cysteine-rich 
domains (CRD)[3]. However, TNFR1 and TNFR2 are Oncotarget 225 www.impactjournals.com/oncotarget
quite different in their intracellular regions. TNFR1 
contains a Death Domain (DD) responsible for triggering 
apoptosis whereas TNFR2 signals depend on the binding 
of several TRAF proteins and does not trigger apoptosis. 
TNFR1 is a ubiquitous receptor the activity of 
which can result in either cell proliferation or cell death 
depending on the cell line and the microenvironmental 
conditions. Upon binding of TNF to TNFR1, different 
signalling complexes may be formed [4]. Complex I is 
a transmembrane complex leading to proliferative signals 
mainly mediated by NF-kB. The activation of TNFR1 
also implies the internalization of the receptor and the 
formation of Complex II or DISC (Death Inducing 
Signalling Complex), implicated in the induction of 
apoptosis [5]. When caspases are inhibited however, 
Complex II is unable to trigger apoptosis, leading to the 
formation of a third complex named Necroptosome [6, 7] 
that is involved in the induction of necroptosis [8, 9]. 
TNFR2 is not so well characterized. The facts 
that TNFR2 expression is restricted to certain cell types 
[10] and that this receptor is activated only by mTNF 
[1] have contributed to this lack of information. After 
ligand binding, TNFR2 binds TRAF2 directly. Some 
other adaptor proteins such as TRAF1, TRAF3, Cellular 
Inhibitor of Apoptosis 1 (cIAP1) and cIAP2 bind to the 
receptor through TRAF2 [11, 12]. Thus, TRAF2 is a 
key mediator in receptor signalling [13]. TRAF2 binds 
to TNFR2 through two different sites in its intracellular 
region. The first site is comprised of amino acids 402-
SKEE-405 and fits into the known TRAF binding site 
of the TNFR superfamily of receptors [12]. A second 
TRAF2 binding site has been recently identified by us 
[14] and is comprised of the last 15 amino acids at the 
C-terminal region of the receptor, being residues 425-
KPL-427 directly responsible for this interaction. TNFR2 
activation implies the induction of genes implicated in 
cell proliferation through NF-kB and N-terminal Jun 
Kinase (JNK) [15-17]. More recently it has been shown 
that TNFR2 and other receptors belonging to the TNFR 
superfamily induce TRAF2 degradation[18, 19]. We 
have shown that amino acids 343-349 are responsible 
for this action [14] although little is known about the 
molecular mechanisms implicated. TNFR2-induced 
TRAF2 depletion may lead to cell death because survival 
and proliferative signals triggered by both TNFR1 and 
TNFR2 depend on TRAF2. In this work we show that 
TRAF2 depletion leads to an enhanced cytotoxicity 
mediated by TNFR1 which correlates with the inhibition 
of NF-kB when both receptors are coexpressed and that 
TNFR2 mutants unable to induce TRAF2 degradation 
fail to enhance cytotoxicity. We also show that TRAF2 
degradation does not rely on its interaction with the 
receptor. In an attempt to study independently the signals 
triggered by TNFR1 and TNFR2 as well as their croostalk 
we have developed a system stably expressing the 
chimeric receptor RANK-TNFR2 in cells carrying only 
endogenous TNFR1. RANK-TNFR2 triggers the same 
signals than TNFR2 but it is activated by RANKL. Thus, 
in these cells TNFR2 is selectively activated by RANKL 
while TNFR1 is selectively activated by sTNF. We show 
that, indeed, coactivation of TNFR1 and RANK-TNFR2 
leads to an enhanced cytotoxicity provided that TNFR2 
activation leads to TRAF2 depletion, rather than NF-kB 
activation.
RESULTS
TNFR2 affects the signals triggered by TNFR1. 
TNFR1 and TNFR2 differ in their intracellular 
regions (Fig 1A). TNFR1 contains a Death Domain 
whereas TNFR2 contains no Death Domain. Instead, 
TNFR2 contains two TRAF2 binding sites [4]. Although 
TNFR1 contains no TRAF2 binding sites, TRAF2 
appears responsible for triggering signals initiated by both 
receptors. Both TNFR1 and TNFR2 activate NF-kB [15, 
20] Oligomerization of the receptors after ligand binding 
or by overexpression is the initial step in their function. 
We have studied TNFRs signalling by overexpressing 
them in the absence of the ligand.
Transient transfection of HEK293 cells with 
increasing amounts of either TNFR shows that the 
activation of NF-kB behaves differently depending 
on the receptor. Thus, when TNFR1 is expressed the 
activity of NF-kB increases as the amount of receptor 
increases (Fig 1B, left panel). On the other hand, when 
TNFR2 is expressed the activation of NF-kB shows a 
biphasic behaviour: at low receptor concentrations NF-
kB activation increases with the amount of receptor but 
at high receptor concentrations NF-kB is inhibited (Fig 
1B, middle panel). We have investigated the consequences 
of coactivation by overexpressing both receptors. As 
shown in Fig 1B (right panel) NF-kB is activated when 
both receptors are coexpressed. However, high TNFR2 
concentrations lead to the inhibition of NF-kB, resembling 
what happens when TNFR2 alone is overexpressed. 
Interestingly enough, coexpression of TNFR1 and 
TNFR2 also lead to an enhanced cytotoxicity (Fig 1C). 
As expected, expression of TNFR1 caused apoptosis in 
HEK293 cells despite the fact that NF-kB was activated 
while expression of TNFR2 had no effect on cell viability. 
When TNFR1 and TNFR2 were coexpressed, the apoptotic 
effect of TNFR1 was enhanced (Fig 1C). Thus, TNFR2 
activation has a dual consequence on TNFR1 signalling: 
a) it negatively affects the activation of NFkB and b) an 
enhanced cytotoxicity can be observed. These results point 
to a critical TNFR1-TNFR2 crosstalk in which TRAF2 
appears as the critical mediator [21].When analyzing the Oncotarget 226 www.impactjournals.com/oncotarget
intracellular levels of TRAF2 in cells expressing TNFR2 
we observed that high receptor expression induces the 
depletion of the adaptor protein (Fig 1D, upper panel) 
which may explain why NF-kB is so poorly activated at 
these receptor concentrations (Fig 1B). As for TNFR1, 
this receptor is unable to induce TRAF2 degradation (Fig 
1D, middle panel). Moreover, when both receptors are 
co-expressed together with TRAF2, TNFR2 also induces 
TRAF2 degradation, indicating that at high concentrations 
of both TNFR1 and TNFR2 the biological effects shown 
occur at low levels of TRAF2 (Fig 1D, lower panel).
TRAF2 binding and TRAF2 degradation depend 
on different TNFR2 regions.
To study the role of TRAF2 depletion on NF-κB 
activation we generated several TNFR2 mutants in which 
Figure 1: TNFR2 expression affects TNFR1 signalling. A) Schematic representation of TNFR1 and TNFR2. Extracellular and 
transmembrane regions of each receptor are represented in black while the intracellular region is shown in light grey. In both receptors the 
main regions involved in their biological functions are also indicated: the DD in TNFR1 (amino acids 328-408), whereas in TNFR2 both 
the regions involved in TRAF2 depletion (amino acids 343-379) and TRAF2 binding sites (amino acids 402-405 and 425-427) are shown. 
B) NF-kB activation by TNF receptors. HEK 293 cells were transiently transfected with the indicated amounts of each expression vector 
encoding TNFR1 or TNFR2, as indicated, together with 0.5 µg of pNF-kB-luc and 0.5 µg of pRL-TK. Forty-eight hours later luciferase 
was determined in cell extracts as indicated in Materials and Methods. Expression of each receptor was also analyzed by western blot (anti-
TNFR1 and anti-FLAG). C) Quantification of the sub G0/G1 population induced by TNF receptors. HEK293 cells were transfected with the 
indicated amounts of receptor-coding plasmids together with 0.2 µg of pGEGF-F. Forty-eight hours later, cells were harvested, stained with 
propidium iodide and analyzed by flow cytometry to quantify the sub G0/G1 population. The percentage of hypodiploid cells is indicated in 
each case. D) Analysis of the intracellular levels of TRAF2. HEK293 cells were transfected with the amount of the plasmids encoding the 
receptors indicated together with 0.5 µg of pTRAF2. Forty-eight hours later the intracellular levels of TRAF2 were determined by western 
blot.
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amino acids responsible for TRAF2 binding were mutated. 
We also generated several mutant receptors in which some 
of the amino acids comprising the TRAF2 degradation site 
were mutated (Fig 2A) [14]. After transfection of HEK293 
cells with these mutant receptors the activation of NF-kB 
was determined. Mutation of amino acids 402-SKEE-405 
to 402-SKAA-405 and amino acids 425-KPL-427 to 425-
AAA-427 (receptor TNFR2-BKO) obliterated the ability 
of TNFR2 to induce NF-kB activation (Fig 2B) but it was 
still able to induce TRAF2 depletion. These amino acids 
Figure 2: Effect of TNFR2-induced TRAF2 depletion on NF-kB activation by TNFR1. A) Schematic representation of 
TNFR2 and its mutants. Representation of the receptor is as in Figure 1A. Numbers indicate the amino acid position in the full-length 
human receptor. Letters in black indicate the mutated amino acids. Their activity for TRAF2 binding or TRAF2 degradation is indicated on 
the right. B-F) NF-kB activation caused by TNFR2 or its mutants. HEK293 cells were transiently transfected with the indicated amounts 
of each expression vector encoding TNFR2 or its mutants, together with 0.5 µg of pNFkB-luc and 0.5 µg of pRL-TK. Forty-eight hours 
later both luciferase activities were determined as described in Materials and Methods. Expression of the receptors was also determined 
by western blot. G-K) NF-kB activation caused by coexpression of TNFR1 and TNFR2 or its mutants. NF-kB activity was determined as 
above. Expression of TNFR1 and TNFR2 or its mutants was determined by western blot.
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comprise the two TRAF2 binding sites[12, 14]. Receptors 
in which aminoacids 343-349 were mutated were unable 
to induce TRAF2 degradation regardless of whether 
they were able to bind TRAF2. Thus, receptors unable 
to bind and to induce TRAF2 degradation (receptors 
TNFR2-BKO-AAD and TNFR2-BKO-DAA) showed a 
much lower capacity to activate NF-kB (Figs 2C and 2D) 
indicating that the interaction between the receptor and 
TRAF2 is essential for the activation of NF-kB. Moreover, 
when expressing TNFR2 mutant receptors able to bind 
TRAF2 but unable to induce its degradation (receptors 
TNFR2-AAD and TNFR2-DAA) the activation of NFkB 
increased as the amount of receptor was higher (Figs 2E 
and 2F). These receptors clearly differ from the wild type 
TNFR2 in which the activation of NF-κB shows a biphasic 
behaviour (Fig 1B), thus pointing to TRAF2 depletion as a 
regulatory action in TNFR2 signalling. 
We next addressed the question of whether TNFR2-
induced TRAF2 depletion affects the activation of NF-kB 
by TNFR1. For this purpose TNFR1 was coexpressed 
with increasing amounts of mutant receptors derived 
from TNFR2 and the activation of NF-kB was studied. 
The coexpression of TNFR1 and TNFR2-BKO (a receptor 
unable to bind TRAF2) resulted in a decrease of NF-kB 
activity as the amount of mutant receptor was increased 
(Fig 2G), similar to what happened when TNFR1 and wild 
type TNFR2 were coexpressed. However, when TNFR1 
was coexpressed with a TNFR2 mutant unable to bind 
and to induce TRAF2 degradation, NF-kB activation 
was not affected by the mutant receptors (Figs 2H and 
2I). Moreover, when TNFR1 was coexpressed with 
TNFR2 mutants in which the TRAF2 degradation site 
was mutated, NF-kB activity increased as the amounts of 
mutant receptors were increased (Figs 2J and 2K). These 
receptors (TNFR2-AAD and TNFR2-DAA) were able 
to bind TRAF2 and therefore to activate NF-kB. Taken 
together, these results show that TNFR2-induced TRAF2 
depletion has a negative regulatory role on TNFR1 
signalling and that the primary action of this regulatory 
role is the inhibition of NF-kB.
TRAF2 depletion by TNFR2 is responsible for the 
enhancement of cytotoxicity driven by TNFR1. 
As shown above, TNFR2 activation increases the 
cytotoxic effect of TNFR1 (Fig 1C). We have also shown 
Figure 3: Effect of TNFR2-induced TRAF2 depletion on TNFR1 cytotoxicity. HEK293 cells were transfected with: A) 1 µg 
of control plasmid or plasmid coding for TNFR1 plus 0.2 µg of pGEGF-F; B) 1 µg of the indicated receptor-coding plasmids plus 0.2 µg of 
pGEGF-F; C) 1 µg of the indicated receptor-coding plasmids and 1 µg of plasmid coding for TNFR1 plus 0.2 µg of pGEGF-F. TNFR2 and 
its mutants are named as in Figure 2 and the symbols B and D in the box under panel B refer to their ability to bind or to degrade TRAF2. 
Forty-eight hours later, cells were harvested, stained with propidium iodide and analyzed by flow cytometry to quantify the sub G0/G1 
population. The percentage of apoptotic cells is indicated in each case.Oncotarget 229 www.impactjournals.com/oncotarget
that TRAF2 depletion by TNFR2 negatively affects NF-kB 
activation (Fig 1B). We therefore addressed the question 
of whether TRAF2 degradation could be linked to the 
increased cytotoxicity observed when TNFR1 and TNFR2 
are coexpressed. For this purpose TNFR1, TNFR2 or 
mutant receptors derived from the latter were expressed in 
HEK293 cells and levels of cell death were determined. As 
expected, neither wild type TNFR2 nor mutant TNFR2s 
unable to bind TRAF2 or to induce TRAF2 degradation, 
were able to induce cell toxicity by themselves (Fig 3B).
When these receptors were coexpressed with TNFR1 
two different behaviours were distinguished. On one 
hand, when TNFR1 was coexpressed with TNFR2-
BKO a enhanced cytotoxicity was observed which was 
comparable to that obtained by coexpression of TNFR1 
and wild type TNFR2. TNFR2-BKO is a mutant receptor 
unable to bind TRAF2 or to activate NF-kB but that retains 
its ability to induce TRAF2 degradation. On the other 
hand, when TNFR1 was coexpressed with TNFR2 mutant 
receptors unable to degrade TRAF2, no enhancement of 
TNFR1 cytotoxicity was observed regardless of whether 
the receptor was able or not to bind TRAF2 (Fig 3C). All 
these results show once again that TRAF2 binding (and 
hence activation of NF-kB) and TRAF2 depletion are 
independent features of TNFR2 and also strongly suggest 
that TRAF2 depletion induced by TNFR2 is a key event 
Figure 4: Functional analysis of the chimeric receptor RANK-TNFR2. A) Schematic representation of TNFR2 and RANK-
TNFR2. The representation of the receptors is as in Fig. 1A. The chimeric receptor RANK-TNFR2 contains residues 1-241 corresponding 
to the extracellular and transmembrane domains of RANK and residues 267-439 corresponding to the intracellular region of TNFR2. 
B) NF-kB activation. HEK293 cells were transiently transfected with the indicated amounts of each expression vector encoding TNFR2 
or RANK-TNFR2, together with 0.5 µg of pNF-kB-luc and 0.5 µg of pRL-TK. Forty-eight hours later luciferase was determined in all 
extracts. C) Analysis of c-Jun phosphorylation. HEK293 cells were transfected with the indicated amounts of TNFR2 or RANK-TNFR2 
expression vectors and with 1 µg of pHA-JNK. After 48 hours, cells were harvested and JNK was immunoprecipitated followed by an 
in vitro c-Jun phosphorylation assay. Its levels were determined by western blot assay using anti-phospho-cJun. D) TRAFs interaction 
assay. HEK293 cells were transfected with 1 µg of each expression vector encoding TNFR2 or RANK-TNFR2 together with 0.5 µg of the 
plasmids encoding the adaptor proteins TRAF1, TRAF2 or TRAF3. Twenty-four hours later, the cells were harvested and the receptors 
immunoprecipitated. The presence of each adaptor protein in the immunoprecipitates was analyzed by western blot (anti-TRAF1, anti-
TRAF2 or anti-TRAF3). E) Analysis of TRAF2 intracellular levels. HEK293 cells were transfected with 1 µg of the plasmids encoding the 
indicated receptors together with 0.5 µg of pTRAF2. Forty-eight hours later the intracellular levels of TRAF2 were determined by western 
blot analysis. F) Quantification of sub G0/G1 populations induced by TNFR2 or RANK-TNFR2. HEK293 cells were transfected with the 
indicated amounts of the plasmids encoding the receptors together with 0.2 µg of pGEGF-F. Forty-eight hours later cells were harvested, 
stained with propidium iodide and analyzed by flow cytometry to quantify the sub G0/G1 population. The percentage of apoptotic cells is 
indicated in each case.
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in TNFR1-TNFR2 functional crosstalk. Thus, by lowering 
intracellular TRAF2 levels all NF-kB-dependent pathways 
are inhibited while TNFR1 induced cell death is enhanced.
A chimeric receptor activated by RANKL but 
bearing the intracellular region of TNFR2 also 
enhances TNFR1 cytotoxicity.
The results reported up to now were obtained 
by transient overexpression of the receptors and their 
activation triggered by oligomerization in the absence 
of the ligand. We therefore addressed the question of 
whether in conditions in which the receptors are not 
overexpressed the TNFR1-TNFR2 crosstalk also occurs. 
Two different problems needed to be solved for this 
approach: a) although TNFR1 is ubiquitously expressed, 
TNFR2 expression is much more restricted in terms of 
cell type, b) TNFR2 is efficiently activated only by mTNF 
which also activates TNFR1; TNFR1 can be activated by 
soluble TNF as well. So, there are no specific ligands that 
independently activate TNFR1 and TNFR2. We solved 
this problem by generating a chimeric receptor RANK-
TNFR2 in which the extracellular and transmembrane 
regions of Receptor Activator of NF-kB (RANK) were 
fused to the intracellular region of TNFR2 (Fig 4A). We 
first checked that this chimeric receptor is functionally 
equivalent to wild type TNFR2. Thus, by overexpressing 
this receptor in HEK-293 cells a biphasic activation of NF-
kB was observed (Fig 4B). Also, RANK-TNFR2 induces 
c-Jun phosphorylation (Fig 4C), binds TRAF1, TRAF2 
and TRAF3 (Fig 4D) and is also able to induce TRAF2 
degradation (Fig 4E). Moreover, when the chimeric 
receptor was coexpressed with TNFR1 it also enhanced 
TNFR1-mediated cytotoxicity (Fig 4F).
In order to test the crosstalk between ligand-
activated receptors, the chimeric receptor RANK-TNFR2 
or its mutant RANK-TNFR2-∆343 were stably expressed 
in the murine cell line L929. L929 cells do not express 
RANK and hence, NF-kB is not activated by RANKL 
(data not shown). Thus, the new L929 derived cell lines 
(L929-RANK-TNFR2) are the appropriate tools to 
Figure 5: Enhancement of TNFR1-mediated cytotoxicity by activation of RANK-TNFR2 with RANKL. Measurement of 
cell viability: L929 cells stably expressing the chimeric receptor RANK-TNFR2 (A) or RANK-TNFR2-∆343 (D) were treated with soluble 
TNF to selectively activate TNFR1, pretreated with RANKL for the indicated times to selectively activate RANK-TNFR2 or with both 
cytokines. After 48 h cell viability was determined by staining with crystal violet and quantified as indicated in Materials and Methods. Data 
represent the quantification of such experiments carried out in triplicates. The error bars represent the error of the mean. Measurement of 
cell death markers. L929 cells stably expressing the chimeric receptor RANK-TNFR2 (B and C) or RANK-TNFR2-∆343 (E and F)) were 
treated for 48 h with TNF, RANKL or both (in this case cells were pretreated with RANKL for 8h). Cells were harvested and apoptosis/
necrosis markers (AnnexinV or 7-AAD) were quantified by flow cytometry as indicated in Materials and Methods. B and E panels show 
the flow cytometry analysis and the gating carried out. C and F panels show the quantification of the results. 
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study the signalling and the crosstalk of ligand-activated 
TNFR1 and TNFR2. In this system, TNFR1 is activated 
by sTNF and TNFR2 (RANK-TNFR2) is activated by 
RANKL. Ligand activated RANK-TNFR2 shows the 
same properties that were shown above for the transiently 
expressed receptor (data not shown).
We analyzed cell viability by measuring crystal 
violet staining when L929-RANK-TNFR2 cells 
were treated with RANKL, sTNF or both ligands 
simultaneously.  Treatment of cells for 48 h with both 
sTNF and RANKL induced a significant increase in TNF 
cytotoxicity compared to that caused by TNF alone. When 
cells were pre-treated with RANKL for a period of as little 
as 0.5 h prior to the combined treatment, the increase in 
cytotoxicity was more pronounced. Thus, pre-treatment 
with RANKL for 4 h increased TNF cytotoxicity 48 h 
later from 40% to 80% (Fig 5A). We also analyzed the 
cell death markers annexin-V and 7 amino actinomycin 
D (7-AAD). As shown in Fig 5B and 5C, treatment with 
RANKL  did  not  induce  significant  changes  in  either 
marker. Soluble TNF induced a very significant increase 
(from 2.95% to 49.8%) in annexin-V positive cells and 
also a significant increase (from 2.98% to 11.73%) in 
annexin-V/7-AAD  positive  cells.  More  importantly, 
co-treatment of cells with sTNF and RANKL further 
increased the percentage of annexin-V and annexin-V/7-
AAD positive cells compared to the values obtained with 
sTNF alone (from 49.8% to 68.35% for annexin-V positive 
cells and from 11.73% to 16.15% for annexin-V/7-AAD 
positive cells, Fig 5B and 5C). To further confirm that the 
cytotoxicity observed after the combined treatment with 
RANKL and sTNF was due to TRAF2 depletion induced 
by TNFR2 we generated the L929-derived cell line named 
L929-RANK-TNFR2-∆343. These cells stably express 
the chimeric receptor RANK-TNFR2-∆343 in which the 
intracellular region has been deleted from aminoacid 343, 
therefore missing residues 343-349 responsible for TRAF2 
degradation. Pretreatment of L929-RANK-TNFR2-∆343 
cells with RANKL did not induce any further increase in 
toxicity over the one caused by sTNF alone, as determined 
by crystal violet staining (Fig 5D). Similar results were 
observed when apoptosis markers were studied. Thus, 
treatment of L929-RANK-TNFR2-∆343 cells with sTNF 
alone induced a significant increase in annexin-V positive 
cells (from 5.86% to 28.93%) though it was lower than in 
L929-RANK-TNFR2 cells (Fig 5E and 5F). Co-treatment 
of cells with sTNF and RANKL induced a very small 
increase in annexin-V or annexin-V/7-AAD positive cells 
compared to the values obtained with sTNF alone (Fig 
5E and 5F). Altogether, these results confirm that ligand 
activation of TNFR1 triggers an apoptotic process that 
may be enhanced by ligand activation of TNFR2, provided 
that the signalling pathway leading to TRAF2 depletion 
prevails over the signalling pathways leading to NF-kB 
activation.
DISCUSSION.
Since TNFR1 and TNFR2 were identified [22], the 
biological functions of TNFR2 have remained elusive 
because of its restricted expression and also because it 
is only efficiently activated by membrane bound TNF 
that also binds and activates TNFR1. TNF binding to 
TNFR2 forces its trimerization which leads to its direct 
interaction with TRAF2 and also with TRAF1, TRAF3, 
cIAP1 and cIAP2 through their binding to TRAF2 [11, 
23]. This results in the activation of NF-kB through both   
the cannonical and the non cannonical pathways [15, 16, 
24] and JNK[25] which lead to transcriptional activation 
of genes related to cell proliferation and survival. Thus, 
TRAF2 acts as a key mediator in TNFR2 signalling 
[11].The translocation of this Signalling Complex to 
the cytoplasm depends on cIAP1 and cIAP2. Several 
intermediates of the interaction TRAF2-cIAPs have 
been identified [26] [27]. Also, MEKK1 undergoes an 
autophosphorylation that activates it, leading to the late 
phosphorylation and activation of JNK [17]. 
TNFR2 activation induces changes in the 
subcellular localization of TRAF2 [28, 29 ]. Upon TNFR2 
stimulation TRAF2 translocates to a new compartment[16, 
19, 30, 31] where the adaptor protein is K48-linked, 
ubiquitinated  and  finally  degraded  by  the  proteasome 
[18, 29, 32, 33] although it has been also proposed that 
TRAF2 degradation takes place in the lysosome [34], 
being cIAP1 identified in both cases as the E3 ligase 
responsible for TRAF2 degradation. We have shown that 
NF-kB is activated with different efficiencies as increasing 
amounts of TNFR2 are expressed and that the extent of 
activation correlates with changes in TRAF2 concentration 
[14]. Amino acids 343-349 of the receptor appear to be 
responsible for the induction of TRAF2 degradation, 
which negatively regulates TNFR2-induced NF-kB 
activation.  This region is constituted of 6 serine residues 
of which 4 show a high score for being phosphorylation 
sites, thus pointing to a phosphorylation of the receptor 
as the origin of TRAF2 depletion. Mutations of these 
serine residues abolish the ability of TNFR2 to degrade 
TRAF2 [14]. Interestingly, whereas signal triggering 
requires TRAF2 binding to the receptor, signal termination 
(TRAF2 depletion) appears independent of TRAF2 
binding. Thus, a TNFR2 receptor unable to bind TRAF2 
is still able to induce its degradation. TNF can induce 
another TRAF2 ubiquitination pattern, implicating K63-
linked polyubiquitin chains, a modification not related 
to degradation but to JNK activation [32]. In this regard 
TRAF2 interaction with ubiquitin proteases such as USP31 
(Ubiquitin Specific Protease) or CYLD (Cylindromatosis) 
which  show  specificity  for  K63-linked  polyubiquitin 
chains is interesting [35, 36]. It is therefore conceivable 
that  TRAF2  is  initially  modified  through  K63-linked 
polyubiquitin chains, converted into an active signal 
transducer and then, through K48-linked polyubiquitin Oncotarget 232 www.impactjournals.com/oncotarget
chains, tagged for degradation, thus terminating TRAF2-
dependent signals. 
TNFR2 does not present a DD domain on its 
intracellular region and it is therefore unexpected of 
inducing cell death by itself. However, some studies 
have pointed to the fact that TNFR2 is able to induce 
cytotoxicity [37, 38]. Several researchers have pointed 
to the fact that TNFR2 could potentiate TNFR1 
cytotoxicity[14, 39, 40]. In one case it has been shown 
that it does so by the inducing TNF production[41]. Here 
we show that TRAF2 depletion by TNFR2 is a negative 
feedback for NF-kB activation which has an important 
effect on TNFR1 signalling, resulting in the increased 
cytotoxicity induced by this receptor. This crosstalk 
appears to not only affect TNFR1 since the activation of 
apoptosis by FASL (Fas ligand) has also been reported to 
be affected by TNFR2 [42]. Thus, the ability of TNFR2 
to induce TRAF2 degradation and therefore its depletion 
results in the inhibition of the antiapoptotic pathways and 
in the enhancement of the cytotoxicity mediated by TNFR1 
when both receptors are coexpressed and activated. For 
an in depth characterization of the crosstalk between 
both TNF receptors we have studied the implication of 
different TNFR2 regions on TNFR1 signalling. It was 
known that TNFR2 signalling relies on TRAF2 binding to 
the region 402-SKEE-405 of the receptor [12]. We have 
shown that TNFR2 presents a second TRAF2 binding site 
located at the C-terminal region of the receptor. A third 
site, which is TRAF2 binding independent, is responsible 
for TNFR2 ability to induce TRAF2 degradation [14]. 
Here we show that this TNFR2 region involved in 
TRAF2 degradation is responsible for the increase in 
TNFR1 cytotoxicity when both receptors are activated. 
Evidence that this crosstalk relies on TRAF2 depletion 
comes from our results in which coexpression of TNFR1 
and TNFR2 mutants unable to degrade TRAF2 does not 
affect TNFR1 cytotoxicity (Fig 2 and Fig 3). TRAF2 (as 
well as the anti-apoptotic proteins cIAP1 and cIAP2) 
interaction with TNFR1 inhibits the ability of this receptor 
to induce cell death [39, 40]. When TNFR1 and TNFR2 
are coactivated, TNFR2 induces TRAF2 degradation thus 
affecting the formation of TNFR1 signalling complex, 
preventing the binding of cIAP1 and cIAP2 to TNFR1 
which  finally  enhance  its  apoptotic  potential.  In  this 
regard it is interesting that TRAF1 together with TRAF2 
have been shown to suppress TNFR1 activation of 
apoptosis [43]. Thus, the balance between the apoptotic 
and antiapoptotic signals triggered by TNF determines 
whether the final outcome will be either cell death or cell 
survival. In other words, by activating the same set of 
receptors biological effects as diverse as proliferation or 
cell death can be obtained depending on the quantitative 
balance between the pro- and anti-apoptotic signals. Thus, 
it is particularly interesting to study the regulatory aspects 
of TRAF2 degradation. The coexpression of TNFR1 with 
TNFR2 mutant receptors unable to either bind or degrade 
TRAF2 reinforces the role of the adaptor protein as a 
key element in receptor crosstalk. Our results show that 
NF-kB activation only occurs when TNFR2 is unable 
to induce TRAF2 depletion (Fig 2). Conversely, the 
cytotoxic activity of TNFR1 increases when the receptor 
is expressed together with a TNFR2 receptor that induces 
TRAF2 degradation. 
The absence of an exclusive ligand for TNFR2 is 
the major limiting factor for the study of this receptor. 
In this study we describe the generation of a functional 
system to study TNFR2 itself and also to study TNFR1/
TNFR2 crosstalk. This meant the stable expression of a 
chimeric RANK-TNFR2 receptor in a cellular context 
free of RANK. Thus, cell treatment with RANKL 
activates TNFR2 whereas sTNF activates TNFR1. We 
show that cells treated with both RANKL and sTNF are 
killed more efficiently than those treated with sTNF alone 
(Fig 5), indicating again that the activation of TNFR2 
causing TRAF2 depletion is a biological mechanism to 
enhance TNFR1 cytotoxicity. In this work we show that 
aminoacids 343-349 of TNFR2 have a principal role on the 
signalling pathways triggered by the receptor. Although it 
is not involved in TRAF2 binding it clearly regulates its 
intracellular levels, thus modulating NF-kB activation and, 
subsequently, TNFR1 cytotoxicity. 
In addition to NF-kB, the JNK pathway is almost 
invariably activated by TNF receptors. Blocking of 
the NF-kB dependent pathway leads to sustained JNK 
activation and apoptosis and, conversely, the blocking of 
TNF-induced JNK pathway promotes cell survival [44-
46]. JNK induces cell death through mitochondrial events 
[47, 48]. In most cell types JNK activation by TNF does 
not imply cell death because TNF induces a transient 
activation of JNK [25]. Thus, it is likely that TNFR2-
TRAF2 interaction leads to a transient activation of JNK 
that implies the activation of proliferative pathways 
whereas a further and sustained activation of the kinase 
could lead to cell death in the context of NF-kB inhibition. 
This agrees with the fact that JNK is efficiently activated 
in the conditions reported in this work (results not shown). 
Recent data point to the interaction of the adaptor protein 
AIP1 (ASK1-interacting protein 1, involved in JNK 
activation) with TNFR2 suggesting a TRAF2-independent 
JNK activation by TNFR2 [49]. AIP1 also interacts with 
TNFR1, being involved in JNK activation and apoptosis 
signalling [50]. 
MATERIALS AND METHODS
Cell lines and transfection methodology. 
Human embryonic kidney 293 (HEK 293) and 
murine fibroblastic L929 cell lines were obtained from 
the American Type Culture Collection (Rockville, MD). Oncotarget 233 www.impactjournals.com/oncotarget
GP2 cell line was purchased from Clontech. HEK293 
and GP2 cells were cultured in minimal essential 
medium supplemented with 10% fetal bovine serum, 1% 
glutamine, 0.13% bicarbonate and antibiotics (100 U/
ml Penicillin, 50 mg/ml Streptomycin). L929 cells were 
cultured in Roswell Park Memorial Institute medium 
supplemented with 10% fetal bovine serum and antibiotics 
(100  U/ml  Penicillin,  50  mg/ml  Streptomycin).  For 
transient transfections, HEK 293 cells (2 x 105 cells/well 
on 6-well plates) were seeded and transfected with 4.25 µg 
polyethylenimine (PEI) pH 7.5 with the indicated plasmids 
in each case in 200 µl of DMEM sumplemented with 1% 
of non-esential aminoacids following manufacturer’s 
instructions. For stable transfection of the L929 cells, the 
packaging cell line GP2 was used. GP2 cells (0.6 x 105 
cells/well on 6 well-plates) were seeded and transfected 
with 3 µg of pBABE-puro-RANK-TNFR2 and 1 µg of 
pVSVg using Fugene and following manufacturer’s 
instructions in 1ml of αMEM medium. Twenty-four hours 
later, 2 ml of αMEM medium was added to each well and 
2 additional ml more 24 hours later. Seventy-two hours 
after transfection the medium of GP2 cells containing 
the retroviral particles was collected to infect L929 cells 
together  with  10  µg/ml  of  Polibren.  After  72  hours, 
the positive clones were selected by adding 4 µg/ml of 
puromycin to the medium. 
Plasmids and antibodies. 
Expression plasmid encoding human Myc-tagged 
TRAF2 as well as the plasmids encoding the adaptor 
proteins TRAF1 and TRAF3 have been previously 
described [51]. The NF-қB reporter construct pNF-қB-luc 
encodes luciferase from firefly (Photinus pyralis) under 
the control of a promoter with several қB elements. It 
was a generous gift from Dr. David S. Ucker, from the 
University of Illinois at Chicago. The pRL-TK plasmid 
(Promega) encodes luciferase from Renilla reniformis 
under the control of the Thyminide Kinase promoter 
from HSV-TK herpes virus. The HA-JNK encodes JNK 
protein tagged with the HA antigen. It was a generous gift 
from Dr. Pilar de la Peña, from the University of Oviedo. 
pEGFP-F expresses a farnesylated version of the green 
fluorescent protein GFP and was also a generous gift from 
Dr. David S. Ucker.
Expression plasmids encoding human FLAG-tagged 
TNFR2 (pCMV1-FLAG-TNFR2) and human TNFR1 
(pCDNA3-TNFR1) were a gift from B.B. Aggarwal 
(MD Anderson Cancer Center, Houston, Texas, USA). 
Unless otherwise indicated, TNFR2 constructs used in 
this work were generated by PCR using standard methods 
and the primers indicated in Table SI. To generate point 
mutations by PCR mutagenesis, the Quick Change Site-
Directed Mutagenesis Kit of Strategene was used together 
with the primers indicated in Table SI. The sequences 
of all plasmids generated in this work were verified by 
automated DNA sequencing
Primary antibodies against TRAF1 (G-20), TRAF2 
(C-20), TRAF3 (H-20) and TNFR1 (H-5) were obtained 
from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, 
USA). Anti-FLAG (F3165) and anti-β-actin (A5441) from 
Sigma. Anti-HA antibody was purchased from Roche and 
anti-c-Jun-phospho-Ser73 antibody was obtained from 
Cell Signalling. Secondary antibodies anti-rabbit IgG and 
anti-mouse IgG tagged with fluorophores were purchased 
from LICOR-Biosciences. 
Western blotting. 
Proteins were separated by SDS-PAGE, 
electroblotted onto PVDF membranes (Immobilone-
FL, Millipore), blocked for 1 hour in 5% non-fat milk 
and incubated with the indicated primary antibodies (at 
1:5,000 dilution in TBS-0.1% Tween) and the appropriate 
secondary antibody (at 1:15,000 dilution in 5% non-fat 
milk in TBS-0.1% Tween). Membranes were scanned 
with the Odyssey® Infrared Imaging System (LI-COR 
biosciences).
Transcriptional activity of NF-kB.
NF-kB activity was determined analyzing the 
expression of luciferase. HEK293 cells were transfected 
with 0.2 µg of pNF-kB-luc, 0.05 µg of pRL-TK and with 
the amounts of the plasmids of interest indicated in each 
case. The activities of both luciferases were determined 
with the Dual-LuciferaseTM Reporter Assay System 
kit (Promega) following manufacturer’s instructions. 
Basal activity was considered the one obtained in cells 
transfected with the pCMV1-FLAG vector alone. In all 
cases the data are represented as activation fold over 
the control condition, once corrected the value of firefly 
luciferase activity with the value of Renilla luciferase 
activity. 
Quantification of the hypodiploid cell population.
HEK293 cells were transfected with the plasmids 
of interest together with 0.2 ug of pEGFP-F. After 36 
hours  the  cells  were  collected  (including  any  floating 
cells in the culture medium), washed twice with PBS 
and permeabilized with 1 ml of 70% Ethanol at -20°C 
added drop by drop while vortexed softly. Cells were 
incubated overnight at -20°C. Next, the samples were 
washed twice in PBS and resuspended in 400 µl of 5 µg/
ml PI, 100 µg/ml RNAse in PBS for 15 min in the dark 
at room temperature. Finally, the cell cycle was analysed 
by flow cytometry (Cytomics FC500, Beckman Coulter) 
to quantify variations in the sub G0/G1 population of the 
transfected cells.Oncotarget 234 www.impactjournals.com/oncotarget
c-Jun phosphorylation.
HEK293 cells were transfected with 1 µg of pHA-
JNK and with the plasmids of interest indicated in each 
case. After 36 hours, cells were harvested and resuspended 
in 200 µl of lysis buffer (20 mM Tris-HCl pH 7.5, 150 
mM NaCl, 1 mM EDTA, 1% Triton X-100, 2.5 mM 
sodium pyrophosphate, 1 mM β-glicerophosphate, 1 mM 
sodium orthovanadate, 1µg/ml leupeptin, 1mM PMSF) 
on ice for 5 minutes and centrifugated for 15 minutes at 
13,000 rpm at 4 °C. Equivalent amounts of proteins of 
each sample were incubated with 1 µg of anti-HA for 4 
hours in rotation at 4 °C. Next, each sample was incubated 
with 20 µl of G-protein linked to a Sepharose matrix 
overnight in rotation at 4 °C. The samples were then 
washed twice with 500 µl of lysis buffer and also twice 
with 500 µl of kinase buffer (25 mM Tris-HCl pH 7.5, 
5 mM β-glicerophosphate, 2 mM DTT, 0.1 mM sodium 
orthovanadate, 10 mM MgCl2) for 2 minutes at 5,000 
rpm at 4 °C. The complexes were incubated in 40 µl of 
kinase buffer supplemented with 200 µM ATP and 1 µg of 
GST-c-Jun (Cell Signalling). The reaction was incubated 
at 30 °C for 30 minutes and then stopped with 40 µl of 
Laemmli buffer (62.5 mM pH 6.8 Tris-HCl, 2% SDS, 
10% glycerol, 50 mM DTT, 2.5% β-mercaptoethanol and 
0.01% bromophenol blue). The samples were analyzed 
by Western-Blot using the primary antibody anti-cJun-
phospho-Ser73.
Co-immunoprecipitation assay.
HEK  293  cells  were  cotransfected  with  1μg  of 
the plasmids indicated in each case together with 0.3 μg 
of the plasmids encoding the TRAF protein of interest. 
Twenty-four hours after transfection, cells were harvested 
and lysed in 200 μl of Lysis buffer (20 mM pH 8.0 Tris-
HCl, 150 mM NaCl, 1 mM DTT, 2 mM EDTA, 1% Triton 
X-100, 1 μg/μl leupeptin, 1 μg/μl aprotinin, 2 mM sodium 
orthovanadate). Two 20 μl fractions were collected as 
inputs for the TRAF protein and for the receptor as 
expression controls. The remaining  fraction was incubated 
with 1μg of anti-FLAG antibody at 4 °C in rotation for 
one hour and then with 20 μl of protein G-Sepharose 
beads in rotation at 4 °C overnight. After three washes 
with lysis buffer and an additional one with low salt 
buffer (20 mM pH 8.0 Tris-HCl , 25 mM NaCl, 1 mM 
DTT, 1 μg/μl leupeptin, 1 μg/μl aprotinine, 2 mM sodium 
orthovanadate), the immunoprecipitate was resuspended 
in SDS-sample buffer and subjected, together with inputs, 
to SDS-PAGE and Western blot with anti-TRAF1, TRAF2 
or TRAF3 and anti-FLAG (anti-receptor).
Analysis of cellular viability.
L929 cells were seeded in 12-well plates (1x10 
5 cells/plate) and treated 24 hours later with 5 ng/ml of 
RANKL or TNF or with both cytokines at the times 
indicated. To study the cell viability under each treatment, 
cells were washed once with PBS and fixed with 500 μl 
of a buffer containing 30% ethanol and 20% acetic acid 
during 15 minutes. Next, cells were stained with a 0.4% 
crystal violet solution in 20% ethanol during 15 minutes 
and washed once with H2O. After drying the plates 
overnight, they were destained during 20 minutes with 500 
μl of a buffer containing 40% ethanol and 10% acetic acid. 
To quantify the amount of dye retained in each condition, 
the absorbance of each sample at 580 nm was determined.
Analysis of cell death induction. 
To study the induction of a cell death process, the 
percentage of positive cells for AnnexinV and 7-AAD was 
determined using the AnnexinV PE Apoptosis Detection 
Kit I from BD Pharmingen following the manufacturer’s 
instructions. Briefly, L929 cells were seeded in 12-well 
plates (1x10 5 cells/plate) and 24 hours later treated with 
5 ng/ml of RANKL or TNF or with both cytokines at the 
times indicated. Cells were harvested and washed twice 
with PBS. The percentage of positive cells for Anexin-V 
and 7-AAD was then determined by flow cytometry on a 
Cytomics FC500 (Beckman Coulter) cytometer. 
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